Sign in →

Test Code APGH Alpha-Subunit Pituitary Tumor Marker, Serum

Reporting Name

AlphaSubunit Pituitary Tumor Marker

Useful For

Adjunct in the diagnosis of pituitary tumors

 

As part of the follow-up of treated pituitary tumor patients

 

Differential diagnosis of thyrotropin-secreting pituitary tumor versus thyroid hormone resistance

 

Differential diagnosis of constitutional delay of puberty versus hypogonadotrophic hypogonadism

Method Name

Immunochemiluminescent Assay

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL


Specimen Minimum Volume

0.35 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Frozen (preferred) 90 days
  Refrigerated  7 days

Reject Due To

Hemolysis

Mild OK; Gross reject

Lipemia

Mild OK; Gross OK

Icterus

Mild OK; Gross OK

Other

NA

Reference Values

PEDIATRIC

≤5 days: ≤50 ng/mL

6 days-12 weeks: ≤10 ng/mL

3 months-17 years: ≤1.2 ng/mL

Tanner II-IV*: ≤1.2 ng/mL

 

ADULTS

Males: ≤0.5 ng/mL

Premenopausal females: ≤1.2 ng/mL

Postmenopausal females: ≤1.8 ng/mL

 

Pediatric and adult reference values based on Mayo studies.

 

*Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (±2) years and for girls at a median age of 10.5 (±2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. For boys, there is no proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (adult) should be reached by age 18.

Day(s) and Time(s) Performed

Friday; 11 a.m.

CPT Code Information

82397

LOINC Code Information

Test ID Test Order Name Order LOINC Value
APGH AlphaSubunit Pituitary Tumor Marker In Process

 

Result ID Test Result Name Result LOINC Value
9003 AlphaSubunit Pituitary Tumor Marker 14170-5

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request Form (T729) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/oncology-request-form.pdf)